NBTX
SellHot AirNanobiotix S.A. · Healthcare · France · $2.1B · Avg Vol: $5M/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT NANOBIOTIX S.A.
Read
Nanobiotix S.A. is a clinical-stage biotechnology company focused on revolutionizing cancer treatment through its proprietary NanoXray technology, which uses hafnium oxide nanoparticles to enhance the efficacy of radiotherapy. The company occupies a specialized niche by developing first-in-class nanomedicines designed to improve patient outcomes across various solid tumors, leveraging a unique physical mechanism of action.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.0K | 0 | 34.5M | -13.3M | 34.1M | 663.9% | 37.4M | 39.8M | 45.9M | 16.0% |
| EPS | -1.35 | -1.88 | -1.24 | -1.65 | -0.57 | — | -0.58 | — | — | — |
| Shares | 34.8M | 34.9M | 47.1M | 47.4M | 48.4M | +38.9% | 50.8M | — | — | — |
| Debt | 46.0M | 61.1M | 58.1M | 58.5M | 109.5M | 24.2% | 109.4M | — | — | — |
| Equity | 26.8M | -31.1M | -2.1M | -75.5M | -97.1M | — | — | — | — | — |
| Op CF | -29.9M | -42.6M | -14.3M | -22.5M | -38.4M | — | -38.4M | — | — | — |
| Inv CF | -0.2M | 0.2M | -0.4M | -1.1M | -0.7M | — | — | — | — | — |
| Fin CF | -5.2M | -6.5M | 53.7M | -5.9M | 43.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NBTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NBTX | Nanobiotix S.A.(you) | $2.1B | 22 | Sell |
| MEDCL.PA | MedinCell S.A. | $1.0B | 21 | Sell |
| IVA.PA | Inventiva S.A. | $1.1B | 8 | Strong Sell |
| DBVT | DBV Technologies S.A. | $851M | 8 | Strong Sell |
| GNFT.PA | Genfit S.A. | $835M | 36 | Hold |
| VALN | Valneva SE | $610M | 12 | Strong Sell |
| ABVX.PA | ABIVAX Société Anonyme | $9.8B | 11 | Strong Sell |
| TNG.PA | Transgene SA | $259M | 18 | Strong Sell |
| IPH.PA | Innate Pharma S.A. | $243M | 17 | Strong Sell |
| CLLS | Cellectis S.A. | $342M | 6 | Strong Sell |
Peer medians: ROE -34.6% · P/E 22.9x · Gross margin 67.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.